Transforming growth factor α levels in pancreatic fluid

Pancreas

Volumn 40, Issue 2, 2011, Pages 260-264

  Doyle, Courtney J ^a   Agaram, Narasimhan P ^a   Yip Schneider, Michele T ^a   Schmidt, Christian Max ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IPMN; MCN; pancreatic adenocarcinoma; SCA; TGF

Indexed keywords

TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BLOOD LEVEL; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; CYSTADENOMA; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MUCINOUS CYSTIC NEOPLASM; NEOPLASM; ODDI SPHINCTER; PANCREAS; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PANCREAS PSEUDOCYST; PANCREATIC FLUID; PRIORITY JOURNAL; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIANA; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 79951723798     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181f94d2a     Document Type: Article

References (27)

1. Ohhashi K, Murakami Y, Maruyama M. Four cases of Bmucin-producing[ cancer of the pancreas on specific findings of the papilla of Vater. Prog Diagn Endosc. 1982;20:348-351.
2. Schmidt CM, Lillemoe KD. IPMN - controversies in an Bepidemic[. J Surg Oncol. 2006;94(2):91-93.
3. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6(1-2):17-32.
4. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239(6):788-797; discussion 797-799.
5. Matsumoto T, Aramaki M, Yada K, et al. Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol. 2003;36(3):261-265. (Pubitemid 36232639)
6. Pelaez-Luna M, Chari ST, Smyrk TC, et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol. 2007;102(8):1759-1764. (Pubitemid 47206677)
7. Schmidt CM, White PB,Waters JA, et al. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg. 2007;246(4):644-651; discussion 651-654.
8. Serikawa M, Sasaki T, Fujimoto Y, et al. Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification. J Clin Gastroenterol. 2006;40(9):856-862. (Pubitemid 44506933)
9. Bernard P, Scoazec JY, Joubert M, et al. Intraductal papillary-mucinous tumors of the pancreas: predictive criteria of malignancy according to pathological examination of 53 cases. Arch Surg. 2002;137(11):1274-1278. (Pubitemid 35345902)
10. Kubo H, Chijiiwa Y, Akahoshi K, et al. Intraductal papillary-mucinous tumors of the pancreas: differential diagnosis between benign and malignant tumors by endoscopic ultrasonography. Am J Gastroenterol. 2001;96(5):1429-1434. (Pubitemid 32455070)
11. Waters JA, Schmidt CM. Intraductal papillary mucinous neoplasm - when to resect? Adv Surg. 2008;42:87-108.
12. Murakami Y, Uemura K, Hayashidani Y, et al. Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas. J Gastrointest Surg. 2007;11(3):338-344.
13. Fujino Y, Matsumoto I, Ueda T, et al. Proposed new score predicting malignancy of intraductal papillary mucinous neoplasms of the pancreas. Am J Surg. 2007;194(3):304-307. (Pubitemid 47212042)
14. Barton CM, Hall PA, Hughes CM, et al. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol. 1991;163(2):111-116.
15. Chen J, Liu TH. Expression of EGF, TGF-alpha, EGFR and c-erbB2 genes and their gene products in human pancreatic carcinoma cell lines. Zentralbl Pathol. 1994;140(3):265-270.
16. Visser CJ, Bruggink AH, Korc M, et al. Overexpression of transforming growth factor-alpha and epidermal growth factor receptor, but not epidermal growth factor, in exocrine pancreatic tumours in hamsters. Carcinogenesis. 1996;17(4):779-785. (Pubitemid 26129693)
17. Korc M. Potential role of the epidermal growth factor receptor in human pancreatic cancer. Int J Pancreatol. 1990;7(1-3):71-81.
18. Korc M. Growth factors and pancreatic cancer. Int J Pancreatol. 1991;9:87-91.
19. Korc M, Chandrasekar B, Yamanaka Y, et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest. 1992;90(4):1352-1360.
20. Greten FR, Wagner M, Weber CK, et al. TGF alpha transgenic mice. A model of pancreatic cancer development. Pancreatology. 2001;1(4):363-368.
21. Schmid RM, Kloppel G, Adler G, et al. Acinar-ductal-carcinoma sequence in transforming growth factor-alpha transgenic mice. Ann N Y Acad Sci. 1999;880:219-230. (Pubitemid 29349130)
22. Davies N, Kapur P, Gillespie J, et al. Transforming growth factor alpha is trophic to pancreatic cancer in vivo. Gut. 1993;34(8):1097-1098. (Pubitemid 23245362)
23. Kullenberg B, Jansen C, Fredang N, et al. Transforming growth factor alpha (TGF-alpha) increases cell number in a human pancreatic cancer cell line but not in normal mouse pancreas. Int J Pancreatol. 2000;28(3):199-205. (Pubitemid 32424309)
24. Sandgren EP, Luetteke NC, Qiu TH, et al. Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver. Mol Cell Biol. 1993;13(1):320-330. (Pubitemid 23006909)
25. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13(3):565-569.
26. Siveke JT, Einwachter H, Sipos B, et al. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell. 2007;12(3):266-279. (Pubitemid 47333415)
27. Schmidt CM, Yip-Schneider MT, Ralstin MC, et al. PGE(2) in pancreatic cyst fluid helps differentiate IPMN from MCN and predict IPMN dysplasia. J Gastrointest Surg. 2008;12(2):243-249.